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1645Timely and accurate risk stratiﬁcation is a central goal for the
evaluation of patients with acute coronary syndrome (ACS)
(1). Cardiac biomarkers, such as cardiac troponin (cTn), have
proven useful when added to clinical risk indicators to better
identify patients at risk for poor outcomes and, in some cases,
to guide therapy (1). Although the proliferation of candidate
biomarkers in recent years has been remarkable, few have
convincingly improved upon discrimination of risk when
added to established clinical tools (2).However, biomarkers of
hemodynamic stress have emerged to be particularly strong
and potentially useful prognostic indicators in patients with
cardiovascular (CV) disease (3).
See page 1654
C-terminal provasopressin (copeptin), midregional pro-
adrenomedullin (MR-proADM), and midregional pro-atrial
natriuretic peptide (MR-proANP) are emerging biomarkers
of hemodynamic stress that are strongly predictive of poor
outcomes in patients with heart failure (HF) (4–6). Pre-
provasopressin is synthesized by the hypothalamus, and its
stable C-terminal fragment, copeptin, is secreted by the
pituitary gland in equimolar amounts to the less stable,
physiologically active N-terminal peptide, arginine vaso-
pressin (AVP), which acts to increase peripheral vascular
resistance and stimulate reuptake of free water (7,8). AVP is
eliminated from the circulation within minutes, whereas
copeptin is stable for days and serves as a surrogate for
measurement of AVP. MR-proADM is the stable portion
of the prohormone of adrenomedullin, which is released
primarily from the adrenal medulla, and is a potent vaso-
dilator that also inﬂuences cardiac contractility, diuresis, and
natriuresis (9,10). MR-proANP, the midregional epitope of
the prohormone of atrial natriuretic peptide (ANP), stim-
ulates vasodilation, natriuresis, and diuresis, similar to other
natriuretic peptides. We recently reported an independent
association of these biomarkers with CV outcomes in pa-
tients with stable ischemic heart disease (11), and several
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accepted December 17, 2013.promising for improving risk
assessment in patients with un-
stable ischemic heart disease
(4,7,10,12).
Therefore, we investigated the
prognostic performance of these
3 emerging biomarkers of hemo-
dynamic stress (copeptin, MR-
proADM, and MR-proANP) in
a large, well-characterized cohort
of patients with non–ST-segment
elevation acute coronary syn-
drome (NSTE-ACS) as well as
the relative and incremental pro-
gnostic value of these biomarkers
concurrent with traditional clin-
ical risk indicators and a broad
panel of established and emerging
biomarkers, including B-type na-
triuretic peptide (BNP), cTnI,
pregnancy-associated plasma
protein-A (PAPP-A), ST2, and
myeloperoxidase (MPO).
Methods
Patient population. The design
andprimary results of theMERLIN-
TIMI 36 (Metabolic Efﬁciency
With Ranolazine for Less Is-
chemia in NonST-Elevation
Acute Coronary Syndromes–
Thrombolysis In Myocardial In-
farction 36) trial have been
reported previously (13). Patients
eligible for enrollment had at least
10 min of ischemic symptoms at rest and presented with 1 of
the following additional risk indicators: elevated levels of
biomarkers of myonecrosis, ST-segment depression 0.1
mV, a history of diabetes mellitus, or an intermediate to high
(3) Thrombolysis In Myocardial Infarction (TIMI) risk
score. Patients were excluded if they had end-stage renal
disease requiring dialysis, cardiogenic shock, or a life expec-
tancy <1 year. Patients were randomized in a 1:1 ratio to
receive ranolazine or placebo. The protocol (including the
biomarker substudy) was approved by the institutional review
boards, and written consent was obtained from all patients.
Biomarker testing. The protocol speciﬁed that blood
samples were to be obtained at enrollment in serum separator
and ethylenediaminetetraacetic acid–anticoagulated plastic
tubes, and serum and plasma were isolated within 60 min of
sample acquisition. Samples were stored in plastic cryovials
at 20C or colder at the enrolling site until shipped to the
TIMI Clinical Trials Laboratory (Boston, Massachusetts),
where they were maintained at 80C or colder.
Copeptin, MR-proADM, and MR-proANP were
measured in plasma using the Kryptor Compact
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1646immunoanalyzer (Brahms GmbH, Hennigsdorf, Germany).
The limit of detection for copeptin is 4.8 pmol/l with a co-
efﬁcient of variation of 7.6% at 23.9 pmol/l and 3.5% at
93.9 pmol/l. The limit of detection for MR-proADM is 0.05
nmol/l with a coefﬁcient of variation of 3.8% at 0.65 nmol/l
and 3.4% at 4.01 nmol/l, and the limit of detection for MR-
proANP is 2.1 pmol/l with a coefﬁcient of variation of 2.4%
at 92.8 pmol/l and 2.3% at 478.6 pmol/l (14–16). BNP was
measured using the ADVIA Centaur (Siemens Healthcare
Diagnostics, Inc., Deerﬁeld, Illinois). The cut point of 80
pg/ml has previously been established with this assay and
validated for risk stratiﬁcation inACS (1). cTnI wasmeasured
using the sensitive cTnI-Ultra assay using the ADVIA
Centaur (SiemensHealthcare Diagnostics, Inc.), and the 99th
percentile decision limit (0.04 ng/ml) was used for all analyses
(1,17). ST2 was measured using the Presage ST2 assay
(Critical Diagnostics, San Diego, California), and the results
were analyzed using a cutoff of 35 ng/ml (17). PAPP-A was
measured using the Active c-PAPP-A enzyme-linked
immunosorbent assay (Diagnostic Systems Laboratories,
Inc., Webster, Texas), and the results were analyzed using a
cutoff of 6.0 IU/ml on the basis of pilot work (18) by our
group. MPO was measured using Dimension RxL (Siemens
Healthcare Diagnostics, Inc., Deerﬁeld, Illinois) with a
decision limit of 670 pmol/l on the basis of our priorwork (19).
All biomarker testing was performed in the TIMI Clinical
Trials Laboratory by personnel blinded to clinical outcomes
and treatment allocation.
Endpoints. Consistent with our prior work, the primary
endpoint for this assessment of biomarkers of hemodynamic
stress was the composite of CV death or HF (3). These
endpoints as well as myocardial infarction (MI) and recur-
rent ischemia were adjudicated by a blinded clinical events
committee (13). The deﬁnition of MI has been reported in
detail (20), and new or worsening HF was deﬁned as
rehospitalization or prolongation of the index hospitalization
(>24 h) in an acute care facility primarily for the treatment
of HF along with an objective sign of HF.
Statistical analysis. The baseline characteristics of this
patient cohort stratiﬁed by biomarker status were compared
using theWilcoxon rank sum test for continuous variables and
the chi-square test for categorical variables. Plasma concen-
trations of copeptin, MR-proADM, and MR-proANP
were categorized using quartiles with an additional analysis
modeling the markers as continuous variables. Given that
there are no established cut points for these 3 biomarkers in
the setting of ACS, we a priori treated the 75th percentile of
each biomarker as elevated for all of the analyses. Other bio-
markers were categorized by established cut points when
available. Kaplan-Meier failure rates at 30 days and 1 year are
presented. The associations between each biomarker and
clinical outcomes were evaluated using the log-rank test.
Adjusted hazard ratios (HRs) were determined using a Cox
proportional hazards regression model that included variables
in the TIMI risk score (21)d65 years of age, documented
coronary artery disease (CAD), recent severe angina,ST-segment deviation >0.5 mm, prior aspirin therapy, 3
cardiac risk factors (diabetesmellitus, current cigarette smoking,
hypertension, hypercholesterolemia, and family history of
CAD)dtogether with creatinine clearance <60 ml/min and
a history of HF. Copeptin, MR-proADM, MR-proANP,
cTnI, BNP, PAPP-A, ST2, and MPO were each evaluated
individually and then concurrently in an expanded biomarker
model.
The prognostic discrimination of each biomarker was
assessed by comparing the incremental improvement of the
C-statistic and by determining the integrated discrimination
improvement (IDI) and the continuous and category-based
net reclassiﬁcation improvement (NRI) for each biomarker
(22). The IDI represents the difference in the predicted
probabilities between cases and controls in 1 clinical model
compared with that in another model, whereas the NRI
measures the probability that patients will be appropriately
reclassiﬁed to increased risk or decreased risk when adding
biomarkers to the model (23). NRI categories were based
on risk of CV death or HF at 1 year (<4%, 4% to 8%, >8%).
Interaction testing was performed by adding an interaction
term along with the main effects for each biomarker
and randomized treatment (ranolazine vs. placebo) in the
multivariable model. Analyses were performed using Stata
version 10.1 (Stata Corp., College Station, Texas) and R
version 2.13 (R Foundation for Statistical Computing,
Vienna,Austria). A p value (2-tailed) of<0.05was considered
to indicate statistical signiﬁcance. The authors had full access
to and take full responsibility for the integrity of the data.Results
Biomarker distribution and correlation. Copeptin, MR-
proADM, and MR-proANP concentrations were available
at baseline in 4,432 patients with NSTE-ACS (biomarker
distributions are shown in Online Table 1). Patients with
higher concentrations of copeptin, MR-proADM, and
MR-proANP were more likely to be older and have multiple
risk factors for CV disease, including diabetes mellitus,
hypertension, current smoking, prior MI, and history of
HF (Online Tables 2 and 3). The correlations between
copeptin, MR-proADM, and MR-proANP and the
expanded panel of biomarkers are presented in Table 1. As
expected, MR-proANP was strongly correlated with BNP
(r ¼ 0.73, p < 0.001). MR-proANP was also moderately
correlated with MR-proADM (r ¼ 0.57, p < 0.001).
Copeptin was only weakly correlated with other markers of
hemodynamic stress, whereas PAPP-A, ST2, and MPO
were not well correlated with any of the other biomarkers in
this analysis.
Copeptin, MR-proADM,MR-proANP, and CV outcomes.
Elevated baseline concentrations of copeptin, MR-proADM,
and MR-proANP were each individually associated with
a higher risk of CV death or HF and CV death or MI at
30 days and 1 year (all p < 0.001) (Fig. 1, Table 2).
In addition, each of these 3 biomarkers was associated
Table 1 Biomarker Correlation
Copeptin MR-proADM MR-proANP BNP TnI PAPP-A ST2
MPO 0.07 0.11 0.07 0.09 0.17 0.39 0.16
ST2 0.22 0.26 0.23 0.29 0.29 0.07
PAPP-A 0.03* 0.06 0.05y 0.09 0.18
TnI 0.09 0.20 0.16 0.47
BNP 0.21 0.50 0.73
MR-proANP 0.30 0.57
MR-proADM 0.33
p < 0.001 unless otherwise indicated. *p ¼ 0.052. yp ¼ 0.002.
BNP ¼ B-type natriuretic peptide; Copeptin ¼ C-terminal provasopressin; MPO ¼ myeloperoxidase; MR-proADM ¼ midregional pro-adrenomedullin;
MR-proANP ¼ midregional pro-atrial natriuretic peptide; PAPP-A ¼ pregnancy-associated plasma protein A; TnI ¼ troponin I.
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1647with individual outcomes of CV death, HF, and MI (all
p  0.009 at 30 days and 1 year) (Table 2). When assessed
along with established clinical risk predictors plus cTnI
and BNP, high baseline concentrations of copeptin,
MR-proADM, or MR-proANP were each independently
associated with a signiﬁcantly higher risk of CV death
and HF as well as the composite endpoint of CV death or
HF at 30 days and 1 year (all p  0.001) (Table 2). How-
ever, when adjusted for the established risk indicators,
copeptin, MR-proADM, and MR-proANP were not
associated with risk of MI (Table 2). Results were consistent
with the biomarkers analyzed as continuous variables
(Online Tables 4 and 5). Although each marker was asso-
ciated with a higher risk of the composite of CV death, MI,
and recurrent ischemia, after adjustment for clinical risk
factors and cTnI and BNP, only MR-proADM and MR-
proANP remained independently associated with this
composite outcome (Online Table 6).
Interaction. There was no signiﬁcant interaction between
the effect of ranolazine versus placebo and copeptin, MR-
proADM, and MR-proANP with respect to the primary
efﬁcacy endpoint for MERLIN-TIMI 36 (CV death, MI,
or recurrent ischemia) or CV death or HF (pinteraction > 0.05
for each).
Concurrent evaluation of biomarkers. When each bio-
marker was individually added to clinical risk indicators
for the purpose of head-to-head comparison, copeptin,
MR-proADM, MR-proANP, BNP, cTnI, and ST2 each
were strongly associated with CV death or HF at 1 year
(all HRs >1.9; all p < 0.001) (Fig. 2). Copeptin,
MR-proADM, MR-proANP, BNP, and PAPP-A had
signiﬁcant but weaker associations with CV death or MI.
Notably, cTnI was the only biomarker with an HR >2 for
both CV death or HF and CV death or MI.
When assessed using contemporary metrics of discrimi-
nation, copeptin, MR-proADM, and MR-proANP each
signiﬁcantly improved the area under the receiver-operating
curve and reclassiﬁcation of risk of CV death or HF at 1 year
(Table 3). Similarly, BNP, ST2, and cTnI improved
discrimination when added to clinical risk indicators;
however, PAPP-A and MPO did not improve the area
under the receiver-operating curve. Each of thesebiomarkers, with the exception of MPO and ST2, modestly
improved discrimination of the risk of CV death or MI on
the basis of IDI (Table 3). Only cTnI improved all metrics
of discrimination for CV death or MI at 1 year. Table 4
shows the net reclassiﬁcation for CV death or HF on the
basis of pre-determined risk categories (<4%, 4% to
8%, >8%). When added to clinical risk indicators plus cTnI
and BNP, copeptin, MR-proADM, and MR-proANP
each individually resulted in the net reclassiﬁcation of
>10% of patients into new risk categories for CV death or
HF at 1 year (10.2%, 10.7%, and 12.3%, respectively; all
p < 0.001).
When all of the biomarkers were added concurrently
to the same clinical model, copeptin, MR-proADM,
MR-proANP, and BNP continued to be associated with
risk of composite CV death or HF at 1 year (Table 5, Online
Table 5). cTnI was strongly associated with all CV events at
1 year in this expanded model, with all HRs >1.9 (all p 
0.003). Other than cTnI, copeptin, MR-proADM, and
PAPP-A were the only biomarkers that remained indepen-
dently associated with risk of CV death or MI at 1 year.
Discussion
In this analysis of more than 4,400 patients with
NSTE-ACS, we evaluated the prognostic performance of
3 emerging biomarkers of hemodynamic stressdcopeptin,
MR-proADM, and MR-proANPdalone and concurrently
with cTnI, BNP, ST2, PAPP-A, and MPO. We found
that, when adjusted for clinical predictors and each of
these established and emerging biomarkers, copeptin,
MR-proADM, and MR-proANP each were independently
associated with the risk of CV death or HF, performing as
well as or better than established cardiac biomarkers such as
BNP. Interestingly, after adjusting for established clinical risk
predictors and the 7 other biomarkers tested, cTnI had the
most consistent independent association across each of the
CV outcomes examined. Using contemporary statistical tools
(IDI and NRI), we found that copeptin, MR-proADM, and
MR-proANP independently and signiﬁcantly enhanced
prognostic performance and reclassiﬁcation for CV death
or HF. Although not surprising, these biomarkers did
Figure 1 CV Death or HF at 1 Year by Biomarker
Unadjusted Kaplan-Meier estimated 1-year incidence of death or HF with (A)
copeptin, (B) MR-proADM, and (C) MR-proANP. Copeptin ¼ C-terminal provaso-
pressin; CV ¼ cardiovascular; HF ¼ heart failure; MR-proADM ¼ midregional pro-
adrenomedullin; MR-proANP ¼midregional pro-atrial natriuretic peptide;
Q ¼ quartile.
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1648not perform as well for ischemic endpoints. Copeptin,
MR-proADM, and MR-proANP are peptides released in
response to hemodynamic stress without known direct causal
links to atherothrombosis; therefore, what is presently known
about the pathobiology plausibly ﬁts with our observationthat these markers were more strongly associated with the
outcomes of death and HF than with recurrent ACS or
worsening stable coronary disease. Notably, this study pro-
vides a unique concurrent analysis of this pathobiologically
broad group of biomarkers of contemporary interest in a
large well-characterized population with NSTE-ACS with
sufﬁcient power to examine short- and longer-term adjudi-
cated ischemic and HF outcomes.
Emerging biomarkers of hemodynamic stress in ACS.
As the prototypical biomarkers of hemodynamic stress,
BNP and the N-terminal pro–B-type natriuretic peptide
have proven to be among the strongest predictors of mor-
tality in patients with unstable ischemic heart disease
(3,24,25). Moreover, patients with ACS who have elevated
levels of natriuretic peptides experience greater reductions in
adverse CV outcomes with speciﬁc interventions, including
early invasive management (3,26). Over the past 10 years,
our group and others have investigated whether other novel
biomarkers might enhance risk stratiﬁcation when used in
conjunction with a natriuretic peptide.
Investigation of copeptin, MR-proADM, and MR-
proANP has focused on their shared physiological link
to hemodynamic stress and prognostic role in patients
with HF (5,6,24). Among 224 patients with acute MI
and clinical HF from OPTIMAAL (Optimal Trial in
Myocardial Infarction with Angiotensin II Antagonist
Losartan), an elevated copeptin level was a powerful pre-
dictor of all-cause mortality at 33 months (4). Similarly,
levels of adrenomedullin have been shown to be elevated in
HF and are associated with increased mortality in patients
with chronic ischemic left ventricular dysfunction (27). The
N-terminal fragment of the ANP prohormone has been
shown to portend poor prognosis in post-MI patients and
patients with left ventricular dysfunction, but had not pre-
viously been shown to add prognostic information beyond
BNP (24).
Fewer studies have assessed the prognostic value of these
biomarkers in ACS. In an important study of 980 patients
with ACS (80% with ST-segment elevation myocardial
infarction), the LAMP (Leicester Acute Myocardial
Infarction Peptide) study investigators found that copeptin,
MR-proADM, and MR-proANP were associated with risk
of CV death or HF after acute MI, especially in patients
with elevated N-terminal pro–B-type natriuretic peptide
levels (7,10,12). Our study of 4,432 patients extends these
ﬁndings to a larger population with NSTE-ACS, includes
both short- and mid-term adjudicated ischemic and HF
outcomes, and provides concurrent assessment of established
and emerging biomarkers.
Integration with other biomarkers. In this population, we
were able to provide a concurrent assessment of multiple
established and emerging biomarkers. We found that ST2, a
truncated portion of an interleukin-1 myocyte receptor and
marker of hemodynamic stress associated with mortality
and HF (28), added to clinical risk predictors for risk
stratiﬁcation for CV death or HF and maintained an
Table 2 Cardiovascular Outcomes and HRs
Copeptin MR-proADM MR-proANP
Q1–Q3, %*
Q4
p Value
HRy
p Value
(95% CI)
Adjusted HRz
p Value
(95% CI) Q1–Q3, %*
Q4
p Value
HRy
p Value
(95% CI)
Adjusted HRz
p Value
(95% CI) Q1–Q3, %*
Q4
p Value
HRy
p Value
(95% CI)
Adjusted HRz
p Value
(95% CI)
30 days
CVD/HF
(n ¼ 124)
1.6 6.5
<0.001
4.15
<0.001
(2.90–5.92)
2.51
<0.001
(1.73–3.64)
1.4 7.0
<0.001
5.08
<0.001
(3.53–7.30)
2.49
<0.001
(1.66–3.75)
1.2 7.7
<0.001
6.76
<0.001
(4.63–9.88)
2.88
<0.001
(1.79–4.63)
CVD/MI
(n ¼ 201)
3.6 7.5
<0.001
2.12
<0.001
(1.60–2.81)
1.52
0.006
(1.13–2.04)
3.6 7.4
<0.001
2.07
<0.001
(1.56–2.75)
1.32
0.092
(0.96–1.83)
3.5 7.8
<0.001
2.23
<0.001
(1.68–2.94)
1.22
0.28
(0.85–1.75)
CVD
(n ¼ 62)
0.7 3.5
<0.001
4.83
<0.001
(2.90–8.05)
2.77
<0.001
(1.62–4.73)
0.7 3.5
<0.001
4.83
<0.001
(2.90–8.06)
2.37
0.004
(1.32–4.23)
0.6 3.9
<0.001
6.91
<0.001
(4.03–11.9)
3.14
0.001
(1.58–6.23)
HF
(n ¼ 91)
1.2 4.7
<0.001
3.94
<0.001
(2.60–5.96)
2.40
<0.001
(1.56–3.70)
1.0 5.4
<0.001
5.70
<0.001
(3.71–8.77)
2.86
<0.001
(1.76–4.62)
0.8 5.8
<0.001
6.97
<0.001
(4.46–10.9)
2.91
<0.001
(1.67–5.08)
MI
(n ¼ 157)
3.1 5.0
0.004
1.61
0.004
(1.16–2.24)
1.19
0.32
(0.84–1.69)
3.1 5.0
0.004
1.61
0.005
(1.16–2.24)
1.07
0.72
(0.73–1.56)
3.2 4.9
0.009
1.55
0.010
(1.11–2.15)
0.85
0.44
(0.56–1.29)
1 yr
CVD/HF
(n ¼ 308)
5.0 13.2
<0.001
2.80
<0.001
(2.24–3.51)
1.71
<0.001
(1.36–2.17)
4.1 15.8
<0.001
4.16
<0.001
(3.32–5.20)
1.96
<0.001
(1.52–2.53)
3.5 17.7
<0.001
5.60
<0.001
(4.44–7.06)
2.20
<0.001
(1.63–2.97)
CVD/MI
(n ¼ 471)
9.1 16.3
<0.001
1.89
<0.001
(1.56–2.28)
1.32
0.005
(1.09–1.61)
8.5 18.0
<0.001
2.27
<0.001
(1.89–2.73)
1.33
0.008
(1.08–1.64)
8.1 19.2
<0.001
2.60
<0.001
(2.16–3.11)
1.27
0.051
(0.99–1.61)
CVD
(n ¼ 208)
3.3 9.1
<0.001
2.86
<0.001
(2.18–3.76)
1.67
<0.001
(1.25–2.22)
2.9 10.2
<0.001
3.80
<0.001
(2.89–4.99)
1.66
0.001
(1.22–2.27)
2.4 11.6
<0.001
5.21
<0.001
(3.94–6.90)
1.82
0.001
(1.26–2.61)
HF
(n ¼ 177)
2.7 8.4
<0.001
3.48
<0.001
(2.59–4.67)
2.12
<0.001
(1.55–2.89)
2.0 10.6
<0.001
5.71
<0.001
(4.20–7.76)
2.71
<0.001
(1.92–3.82)
1.7 11.4
<0.001
7.38
<0.001
(5.36–10.2)
3.07
<0.001
(2.05–4.62)
MI
(n ¼ 335)
7.0 11.1
<0.001
1.64
0.002
(1.31–2.06)
1.21
0.11
(0.95–1.54)
6.7 11.8
<0.001
1.83
<0.001
(1.47–2.29)
1.14
0.31
(0.88–1.48)
6.6 12.3
<0.001
1.94
<0.001
(1.56–2.42)
1.01
0.94
(0.76–1.35)
*Kaplan-Meier event rate. yUnadjusted HR. zAdjusted for clinical model and established biomarkers (age, CAD, CAD risk factors, repeated rest pain, long-term aspirin therapy, ST-segment depression, history of CHF, creatinine clearance <60 ml/min, BNP, and cTnI).
CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CI ¼ conﬁdence interval; cTnI ¼ cardiac troponin I; CVD ¼ cardiovascular disease; HF ¼ heart failure; HR ¼ hazard ratio; MI ¼ myocardial infarction; Q ¼ quartile; other abbreviations as in Table 2.
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Figure 2 Adjusted Risk of 1-Year Adverse CV Outcomes Associated With Elevation of Individual Biomarkers
Clinical model includes >65 years of age, CAD, CAD risk factors, 2 episodes of rest pain, long-term aspirin therapy, ST-segment depression, history of HF, and creatinine
clearance <60 ml/min. Each biomarker was added to the clinical model individually. BNP ¼ B-type natriuretic peptide; CAD ¼ coronary artery disease; cTnI ¼ cardiac troponin I;
CVD ¼ cardiovascular disease; HR ¼ hazard ratio; MI ¼ myocardial infarction; MPO ¼ myeloperoxidase; PAPP-A ¼ pregnancy-associated plasma protein A; other abbreviations
as in Figure 1.
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1650association with HF at 1 year when combined with all other
biomarkers. Similarly, MPO, a marker of oxidative stress
(19,29), maintained a modest association with HF at 1 year
in this cohort when combined with each of the estab-
lished and emerging biomarkers. PAPP-A, a matrixTable 3 Prognostic Discrimination
C-Statistic
C-Statistic
p Value
NRI
(p Value)
IDI
p Value
CVD or HF at 1 yr
Clinical model 0.748 Reference Reference Reference
þ MR-proANP 0.791 <0.001 0.77 (<0.001) <0.001
þ BNP 0.783 <0.001 0.71 (<0.001) <0.001
þ MR-proADM 0.778 0.001 0.69 (<0.001) <0.001
þ cTnI 0.775 0.002 0.43 (<0.001) <0.001
þ ST2 0.767 0.01 0.43 (<0.001) <0.001
þ Copeptin 0.766 0.01 0.48 (<0.001) <0.001
þ MPO 0.755 0.21 0.23 (<0.001) 0.014
þ PAPP-A 0.749 0.83 0.10 (0.14) 0.21
CVD or MI at 1 yr
Clinical model 0.685 Reference Reference Reference
þ cTnI 0.719 <0.001 0.42 (<0.001) <0.001
þ MR-proADM 0.692 0.09 0.37 (<0.001) <0.001
þ PAPP-A 0.691 0.10 0.16 (0.003) 0.015
þ BNP 0.690 0.30 0.38 (<0.001) <0.001
þ MR-proANP 0.689 0.12 0.36 (<0.001) 0.002
þ Copeptin 0.689 0.51 0.25 (<0.001) 0.003
þ MPO 0.687 0.49 0.10 (0.06) 0.16
þ ST2 0.685 0.93 0.14 (0.009) 0.065
IDI ¼ integrated discrimination improvement; NRI ¼ net reclassiﬁcation index; other abbreviations
as in Tables 1 and 2.metalloproteinase that is a putative marker of coronary
plaque instability (30), was moderately associated with CV
death or MI at 1 year. cTnI, a marker of myocardial necrosis
that is widely validated and used as a diagnostic and
prognostic marker in ACS (31,32), was the only biomarker
independently associated individually with CV death, MI,
and HF when adjusted for clinical risk predictors and all
other biomarkers.
Clinical implications. Current guidelines call for novel
biomarker development to speciﬁcally address the incre-
mental diagnostic and prognostic beneﬁt derived beyond
that of established risk factors (33). In this study, we used
contemporary statistical analyses, including IDI and NRI, to
show improved prognostic discrimination and signiﬁcant
reclassiﬁcation beyond established risk indicators. We found
that copeptin, MR-proADM, and MR-proANP improved
prognostic assessment individually and as part of an
expanded panel, but their role in clinical decision making
in patients with ACS has not been deﬁned and is likely
to require data showing speciﬁc treatment implications to
support routine use. Nevertheless, as suggested previously for
BNP, such an expanded biomarker panel that delivers
enhanced risk stratiﬁcation is likely to be useful for identi-
fying the highest-risk patients who have the most to gain
from effective therapies (3). In addition, we have recently
identiﬁed a therapeutic interaction with MR-proADM and
MR-proANP and treatment with an angiotensin-converting
enzyme inhibitor in patients with stable ischemic heart
disease (11). Our ﬁndings in these 2 separate studies point
toward the potential for these biomarkers to be useful for
Table 4 Reclassiﬁcation for CV Death or HF at 1 Year
Original Risk Category
Risk Reclassiﬁcation
Low Risk
(<4%)
Moderate Risk
(4%–8%)
High Risk
(>8%)
Total
Reclassiﬁed, %
Copeptin
Low risk
(<4%)
n 1,824 97 d d
Reclassiﬁed, % d 5 d 5
Observed event rate, % 1.6 5.2 d d
Moderate risk
(4%–8%)
n 187 514 92 d
Reclassiﬁed, % 23.6 d 11.6 35.2
Observed event rate, % 1 6.4 16.3 d
High risk
(>8%)
n d 133 865 d
Reclassiﬁed, % d 13.3 d 13.3
Observed event rate, % d 3.0 19.1 d
MR-proADM
Low risk
(<4%)
n 1,813 108 d d
Reclassiﬁed, % d 5.6 d 5.6
Observed event rate, % 1.4 8.3 d d
Moderate risk
(4%–8%)
n 198 457 138 d
Reclassiﬁed, % 25 d 17.4 42.4
Observed event rate, % 1.5 5.7 14.5 d
High risk
(>8%)
n d 183 815 d
Reclassiﬁed, % d 18.3 d 18.3
Observed event rate, % d 5.5 19.5 d
MR-proANP
Low risk
(<4%)
n 1,848 72 1 d
Reclassiﬁed, % d 3.7 0.1 3.8
Observed event rate, % 1.6 6.9 0 d
Moderate risk
(4%–8%)
n 295 363 135 d
Reclassiﬁed, % 37.2 d 17.0 54.2
Observed event rate, % 1.7 6.1 16.3 d
High risk
(>8%)
n d 222 776 d
Reclassiﬁed, % d 22.2 d 22.2
Observed event rate, % d 6.3 20.0 d
The original model includes clinical predictors and established biomarkers: age, CAD, CAD risk factors, repeated rest pain, long-term aspirin therapy,
ST-segment depression, history of CHF, creatinine clearance <60 ml/min, BNP, and cTnI.
Abbreviations as in Tables 1 and 2.
Table 5 Biomarkers and Adjusted Risk of Cardiovascular Outcomes
CVD/HF CVD/MI CVD HF MI RI
Copeptin 1.45 (1.11–1.89)
p ¼ 0.007
1.26 (1.01–1.58)
p ¼ 0.043
1.52 (1.10–2.11)
p ¼ 0.01
1.70 (1.18–2.43)
p ¼ 0.004
1.17 (0.89–1.54)
p ¼ 0.26
0.88 (0.71–1.08)
p ¼ 0.21
MR-proADM 1.50 (1.10–2.03)
p ¼ 0.010
1.32 (1.03–1.70)
p ¼ 0.031
1.30 (0.89–1.90)
p ¼ 0.17
1.89 (1.24–2.89)
p ¼ 0.003
1.26 (0.93–1.71)
p ¼ 0.13
1.17 (0.93–1.47)
p ¼ 0.18
MR-proANP 1.77 (1.24–2.51)
p ¼ 0.002
1.09 (0.82–1.44)
p ¼ 0.57
1.61 (1.04–2.48)
p ¼ 0.03
2.14 (1.32–3.48)
p ¼ 0.002
0.91 (0.65–1.28)
p ¼ 0.58
1.28 (0.99–1.66)
p ¼ 0.06
BNP 1.57 (1.10–2.25)
p ¼ 0.014
1.05 (0.81–1.36)
p ¼ 0.70
1.49 (0.97–2.30)
p ¼ 0.07
1.57 (0.95–2.60)
p ¼ 0.08
0.95 (0.71–1.28)
p ¼ 0.74
0.87 (0.7–1.08)
p ¼ 0.21
cTnI 1.96 (1.37–2.80)
p < 0.001
2.60 (1.97–3.45)
p < 0.001
1.91 (1.24–2.95)
p ¼ 0.003
2.54 (1.49–4.34)
p ¼ 0.001
2.96 (2.13–4.13)
p < 0.001
1.24 (1.01–1.51)
p ¼ 0.04
PAPP-A 0.94 (0.68–1.29)
p ¼ 0.69
1.32 (1.02–1.68)
p ¼ 0.032
1.11 (0.76–1.62)
p ¼ 0.59
0.71 (0.46–1.11)
p ¼ 0.13
1.27 (0.94–1.71)
p ¼ 0.12
1.02 (0.81–1.28)
p ¼ 0.88
ST2 1.22 (0.93–1.61)
p ¼ 0.15
0.88 (0.70–1.11)
p ¼ 0.28
0.94 (0.67–1.31)
p ¼ 0.71
1.52 (1.06–2.19)
p ¼ 0.02
0.78 (0.58–1.04)
p ¼ 0.09
0.86 (0.69–1.06)
p ¼ 0.16
MPO 1.23 (0.94–1.60)
p ¼ 0.12
0.99 (0.80–1.22)
p ¼ 0.89
1.16 (0.84–1.61)
p ¼ 0.37
1.55 (1.09–2.20)
p ¼ 0.01
0.96 (0.75–1.24)
p ¼ 0.76
1.12 (0.93–1.34)
p ¼ 0.23
Values are 1-year adjusted risk and are presented as HR (95% CI).
RI ¼ recurrent ischemia; other abbreviations as in Tables 1 and 2.
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1652targeting therapies aimed at preventing adverse remodeling
in patients with ACS, which is a hypothesis that would
require prospective evaluation in clinical studies. If sup-
ported by such evidence, it is possible that clinical applica-
tion of a multimarker panel including these emerging
biomarkers could be applied not only to enhance risk
stratiﬁcation but also to select new or established therapies
aimed at mitigating the risk of HF after ACS.
Interestingly, we found that each of these 3 biomarkers,
which are broad markers of hemodynamic stress, contributed
independently to risk assessment. This apparent comple-
mentary information may derive from the fact that they
have varied stimuli for release and thus potentially capture
different contributors to hemodynamic stress in patients
with ischemic heart disease. In addition, we cannot exclude
as yet unknown other pathological aspects of these bio-
markers or perturbations of the pathways that they signal.
This ﬁnding may stimulate additional translational research
investigating the interaction and interdependence of these
pathways.
Study limitations. As a selected population enrolled in a
clinical trial, the quantitative ﬁndings in our population may
not be generalizable to all patients with ACS, speciﬁcally
patients with fewer cardiac risk factors. Additional studies
in community-based cohorts are likely to be valuable.
Because there are no widely accepted diagnostic or prog-
nostic cut points in ACS for copeptin, MR-proADM,
and MR-proANP, we used categorical comparisons of
biomarkers on the basis of their distribution in quartiles.
Prospective validation of speciﬁc cut points for copeptin,
MR-proADM, and MR-proANP for risk stratiﬁcation
would also be important to guide clinical use. We used a
current-generation, commercially available sensitive cTnI
assay. Notably, the prognostic performance of the newer
biomarkers that we examined was consistent among patients
with and without elevated cTn concentrations. It will be
interesting to study these markers in association with
emerging high-sensitivity assays for cTn; however, on the
basis of this ﬁnding, the application of more sensitive assays
is unlikely to qualitatively alter our conclusions. Also, the
NRI categories were based on our reasoned categorization of
clinically-relevant groupings of risk rather than previously-
established risk groups for secondary prevention, because
these do not presently exist.Conclusions
We found in this large study that copeptin, MR-proADM,
and MR-proANP are robust prognostic markers for CV
death and HF in patients with NSTE-ACS, adding
to known clinical risk indicators plus established and
emerging prognostic biomarkers. Evaluated alongside
emerging biomarkers, cTnI is the most consistent predictor
of CV death, HF, and ischemic events in patients
with ACS.Reprint requests and correspondence:Dr. Marc P. Bonaca, TIMI
Study Group/Cardiovascular Division, Brigham and Women’s
Hospital, 75 Francis Street, Boston, Massachusetts 02115. E-mail:
mbonaca@partners.org.REFERENCES
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